Effective January 1, 2025, all five infliximab IV products below will be covered at parity by Independence Blue Cross (IBX):
- Remicade® (infliximab)
- Renflexis® (infliximab-abda)
- Inflectra® (infliximab-dyyb)
- Avsola® (infliximab-axxq)
- Ixifi™ (infliximab-qbtx)
Please note that the infliximab IV products will still be listed on the precertification list.
Learn more
These changes will be reflected in updated Commercial and Medicare Advantage medical policies in January 2025:
- Commercial:
- #08.00.34 Intravenous Infliximab and Related Biosimilars
- Medicare Advantage:
- #MA08.019 Intravenous Infliximab and Related Biosimilars
To view any pending policy notifications (which signify upcoming changes) or active medical policies, you can visit the IBX Medical and Claim Payment Policy Portal.
Under Active Notifications or Policy Bulletins, select Commercial or Medicare Advantage, based on which version of the policy you want to view. Then, you can search by category, or type the policy name or number in the Search box up top.
For more information on accessing medical policies, refer to our article on Staying updated on Medical Policies.